AR003453A1 - Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores - Google Patents

Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores

Info

Publication number
AR003453A1
AR003453A1 ARP960103538A AR10353896A AR003453A1 AR 003453 A1 AR003453 A1 AR 003453A1 AR P960103538 A ARP960103538 A AR P960103538A AR 10353896 A AR10353896 A AR 10353896A AR 003453 A1 AR003453 A1 AR 003453A1
Authority
AR
Argentina
Prior art keywords
inhibitors
manufacture
preparation
cooh
medicines
Prior art date
Application number
ARP960103538A
Other languages
English (en)
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9514074.5A external-priority patent/GB9514074D0/en
Priority claimed from GBGB9520311.3A external-priority patent/GB9520311D0/en
Priority claimed from GBGB9522837.5A external-priority patent/GB9522837D0/en
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of AR003453A1 publication Critical patent/AR003453A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Abstract

Los compuestos de la fórmula (I) donde B es O o CH2; X se selecciona de NR1 R2, SR1 y alquilo C1-C7; Y se selecciona de SR1, NR1R2 y alquilo C1-C7; R1 y R2es cada uno independientemente selecionado de H, alquilo C1-C7 opcionalmente sustituido eno dentro de la cadena alquila por uno o más de O, S,N o halógeno;R3 y R4 son ambos H, ó R3 y R4 juntos forman un enlace; A es COOH, C(O)NH(CH2)p COOH, C(O)N[CH2qCOOH]2; C(O)NHCH(COOH)CH2), COOH, ó 5-tetrazolil, donde p, q yr son cada uno eindependien temente 1, 2 ó 3; así como las sales farmacéuticamente aceptables y sus prodrogas,procedimiento para su preparación,composiciones farmacéuticas que comprenden a los compuestos nuevos y el uso de los compuestos en lafabricación de med icamentos. Además dentro del enlace dela invención están los intermediarios nuevos para su exclusivo uso en el procedimiento de obtención de los compuestos nuevos. Los compuestos nuevos sonen particular útiles para laprevención del agregado d e plaquetas.
ARP960103538A 1995-07-11 1996-07-11 Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores AR003453A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9514074.5A GB9514074D0 (en) 1995-07-11 1995-07-11 Compounds
GBGB9520311.3A GB9520311D0 (en) 1995-10-05 1995-10-05 Compounds
GBGB9522837.5A GB9522837D0 (en) 1995-11-08 1995-11-08 Compounds

Publications (1)

Publication Number Publication Date
AR003453A1 true AR003453A1 (es) 1998-08-05

Family

ID=27267806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103538A AR003453A1 (es) 1995-07-11 1996-07-11 Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores

Country Status (25)

Country Link
US (1) US5747496A (es)
EP (1) EP0840740B1 (es)
JP (1) JP4084415B2 (es)
KR (1) KR100444123B1 (es)
CN (1) CN1069321C (es)
AR (1) AR003453A1 (es)
AT (1) ATE217010T1 (es)
AU (1) AU699034B2 (es)
BR (1) BR9609467A (es)
CA (1) CA2226758A1 (es)
CZ (1) CZ297200B6 (es)
DE (1) DE69621021T2 (es)
EE (1) EE03616B1 (es)
HU (1) HU221880B1 (es)
IL (1) IL122814A (es)
IS (1) IS1790B (es)
MY (1) MY116542A (es)
NO (1) NO310624B1 (es)
NZ (1) NZ312258A (es)
PL (1) PL182680B1 (es)
SA (1) SA96170272B1 (es)
SK (1) SK283206B6 (es)
TR (1) TR199800019T1 (es)
TW (1) TW427996B (es)
WO (1) WO1997003084A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028300A1 (en) * 1996-12-20 1998-07-02 Astra Pharmaceuticals Ltd. Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
SE9702772D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702774D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702773D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
DE69905451T2 (de) * 1998-02-17 2003-11-20 Astrazeneca Uk Ltd Neue triazolo(4,5d) pyrimidinverbindungen
SE9802574D0 (sv) * 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6897201B2 (en) * 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US20020169730A1 (en) * 2001-08-29 2002-11-14 Emmanuel Lazaridis Methods for classifying objects and identifying latent classes
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
WO2004092170A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
EP1615931A1 (en) * 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
EP1618108A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
US7834014B2 (en) * 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7368438B2 (en) * 2003-10-21 2008-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for inhibiting platelet aggregation
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
JP2007509180A (ja) * 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US7566722B2 (en) * 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AR072938A1 (es) * 2008-08-20 2010-09-29 Southern Res Inst Derivados de piridina y pirimidina azosustituidos y su uso en el tratamiento de infecciones virales
CA2788072A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
BR112014013085A2 (pt) 2011-11-30 2017-06-13 Actavis Group Ptc Ehf forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
JP6145574B2 (ja) * 2013-06-27 2017-06-14 スーヂョウ ミラクファーマ テクノロジ カンパニー リミテッドＳｕｚｈｏｕ Ｍｉｒａｃｐｈａｒｍａ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． チカグレロールの調製方法
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN112915063B (zh) * 2021-01-25 2022-12-20 刘红枚 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
RU2770405C1 (ru) * 2021-07-05 2022-04-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные триазола, проявляющие антиагрегационную активность

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
JP2619710B2 (ja) * 1989-02-27 1997-06-11 日本製紙 株式会社 ２′，３′−ジデオキシプリンヌクレオシド類の製造方法
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
WO1994018215A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives

Also Published As

Publication number Publication date
CA2226758A1 (en) 1997-01-30
US5747496A (en) 1998-05-05
KR19990028885A (ko) 1999-04-15
CN1195353A (zh) 1998-10-07
EE03616B1 (et) 2002-02-15
EP0840740B1 (en) 2002-05-02
ATE217010T1 (de) 2002-05-15
HUP9802448A3 (en) 2000-03-28
SK283206B6 (sk) 2003-03-04
HU221880B1 (hu) 2003-02-28
NO310624B1 (no) 2001-07-30
CZ297200B6 (cs) 2006-09-13
KR100444123B1 (ko) 2004-10-14
WO1997003084A1 (en) 1997-01-30
DE69621021T2 (de) 2002-10-31
MY116542A (en) 2004-02-28
NZ312258A (en) 1999-08-30
CZ2598A3 (cs) 1998-08-12
AU699034B2 (en) 1998-11-19
NO980080D0 (no) 1998-01-08
NO980080L (no) 1998-03-06
IS1790B (is) 2001-11-28
IL122814A0 (en) 1998-08-16
IL122814A (en) 2001-04-30
JP4084415B2 (ja) 2008-04-30
TR199800019T1 (xx) 1998-05-21
JPH11508914A (ja) 1999-08-03
SA96170272B1 (ar) 2006-06-04
AU6375196A (en) 1997-02-10
HUP9802448A2 (hu) 1999-05-28
DE69621021D1 (de) 2002-06-06
SK2398A3 (en) 1999-01-11
TW427996B (en) 2001-04-01
MX9800308A (es) 1998-09-30
EP0840740A1 (en) 1998-05-13
IS4647A (is) 1998-01-08
CN1069321C (zh) 2001-08-08
PL182680B1 (pl) 2002-02-28
BR9609467A (pt) 1999-03-02
PL324396A1 (en) 1998-05-25
EE9800026A (et) 1998-08-17

Similar Documents

Publication Publication Date Title
AR003453A1 (es) Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores
PA8518701A1 (es) Derivados de tiofeno utiles como agentes anticancerosos
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
PA8431301A1 (es) Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
UY26872A1 (es) Derivados de la 4- fenil piridina
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
CO5580771A2 (es) Antagonistas ccr5 como agentes terapeuticos
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
AR035320A1 (es) Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta
AR015712A1 (es) Derivados de 3,4-dihidro-tieno[2,3-d]pirimidina-3-sustituidos y su uso para la preparacion de composiciones farmaceuticas
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
FI970317A (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
ES2155535T3 (es) Inhibidores de sintesis de apoliproteina b.
HRP20020481B1 (en) Condensed azepines as vasopressin agonists
AR015446A1 (es) Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
NO20000737D0 (no) Tetrahydro <gamma>-karboliner
EP0351385A3 (en) New amidino and guanidino derivatives
AR009363A1 (es) Compuestos 3-mercaptoacetilamino-1,5-sustituido--oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz, composicion farmaceutica y usos para la fabricacion de medicamentos para el tratamiento de enfermedades que responden a la inhibicion de metaloproteinasas de la matriz
AR039008A1 (es) Derivados azabiciclicos, azatriciclicos y azaespirociclicos de aminociclohexano antagonistas de los receptores nmda, 5-ht3, y nicotinico neuronal
PA8444901A1 (es) Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
AR005472A1 (es) Inhibidores de la formacion cd23 humana soluble, un procedimiento para su preparacion, el uso de los mismos para la manufactura de un medicamento,composicion farmaceutica y compuestos intermediarios

Legal Events

Date Code Title Description
FG Grant, registration